Aepodia can help pharmaceutical and biotechnological companies developing new classes of compounds requiring specific and in-depth knowledge in various therapeutic areas, by ensuring their phase I/IIa trials are a success, thanks to our solid therapeutic expertise and KOL network. We provide support in designing and optimising drug development plans. Our scientific team has extensive expertise in the central nervous system, cardiovascular, infectious and respiratory diseases, inflammatory states, endocrine and metabolic disorders, oncology and more.
Aepodia has also developed a broad, global network of investigators and academic sites with strong regulatory strategies and drug development know-how for providing tailor-made solutions in specialised proof-of-concept studies such as:
- Cardiovascular (e.g. hypertension, coagulation)
- Inflammatory diseases (RA, OA)
- Respiratory diseases
- Central nervous system
- Metabolic diseases
Our team manages studies in a wide range of fields, including medical imaging, sleep trials, provocative tests, glucose clamps and pain. For these studies, our scientists can implement and recommend clinical plan biomarkers.